fs ...well after a little research
Note ...I have no position in KERX
While they may get expanded approval in Nov they are only a year or two ahead of FGEN with a new drug for non dialysis dependent CKD patients with Iron Deficiency Anemia....and FGEN's data to date looks considerably better
-------------------------
March 2017 FGEN
“We are pleased with the positive data that we have seen from our China clinical development program for roxadustat. The published results from our Phase 2 program continue to show that that roxadustat corrects and maintains hemoglobin levels, maintain iron stores, and decreases levels of hepcidin,” said Chris Chung, FibroGen’s Vice President of China Operations.
In the first study, 91 non-dialysis-dependent patients were dosed over eight weeks, according to two different weight-based dosing regimens.
Hemoglobin levels were increased over baseline by more than 1.0 gm/dL in a significantly greater proportion of patients receiving roxadustat than patients receiving placebo (80% and 87.1% for the low- and high-dose roxadustat arms versus 23.3% in the placebo arm (p<0.0001, both)).
-------------------------------
Similar data from KERX was 52.1% of patients increased hemoglobin by more then 1.0 gm/dl vs 19.1 % on placebo.
Just an FYI
Kiwi
